Tysabri and PML: What Does Your Treatment Timeline Reveal?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Drug Safety

If you or someone you know has taken Tysabri, understanding the timeline of exposure and any symptoms that followed is a critical first step. Decades of pharmacovigilance have established a clear link between this medication and progressive multifocal leukoencephalopathy (PML), a serious brain infection. This page reviews the patient history factors that clinicians consider when evaluating PML risk after Tysabri use.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri exposure, understanding the medical evidence and legal considerations, including the statute of limitations, is critical. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label emphasizes that these factors should be considered when initiating and continuing therapy, and that healthcare professionals must monitor patients for any new signs or symptoms suggestive of PML, withholding Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

PML typically presents with progressive neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed through brain MRI and detection of JC virus DNA in cerebrospinal fluid. The clinical course is often devastating, with most patients experiencing severe disability or death. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. From a risk perspective, the adequacy of warnings regarding Tysabri and PML has been a subject of litigation. The boxed warning and the TOUCH Prescribing Program, which requires patient enrollment and education, represent regulatory efforts to mitigate risk. However, some patients and their families have argued that these warnings were insufficient or that the risks were not adequately communicated before treatment initiation.

Statute of Limitations for Tysabri Claims in Washington

For affected patients in Washington, settlement-related considerations depend on the specific circumstances of exposure and harm. The statute of limitations for personal injury claims in Washington is generally three years from the date the injury was discovered or should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. The label notes that PML can occur after varying durations of treatment, and cases have been reported after a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period complicates the determination of when the injury was discoverable, which is a key factor in statute of limitations calculations. Patients who develop PML after Tysabri treatment may be eligible for compensation through settlements or litigation. Evidence of harm includes medical records documenting PML diagnosis, treatment history with Tysabri, and documentation of risk factors such as anti-JCV antibody status and duration of therapy. The settlement process often involves evaluating whether the manufacturer provided adequate warnings and whether the patient's healthcare provider followed recommended monitoring protocols. In Washington, courts consider the totality of evidence, including the timing of symptoms and diagnosis relative to Tysabri exposure.

Conclusion and Next Steps

In summary, Tysabri-associated PML is a severe adverse event with well-defined risk factors and a clear mechanistic basis. For Washington patients, the statute of limitations for filing a claim is typically three years from discovery of the injury, but the variable latency of PML requires careful assessment of when the harm became apparent. Legal and medical professionals should work together to ensure that affected individuals receive appropriate compensation and support. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or should have been discovered. For PML, the latency period can complicate this timeline, so it is important to consult with an attorney as soon as possible after diagnosis.

What evidence is needed to support a Tysabri PML claim?

Evidence includes medical records documenting PML diagnosis, treatment history with Tysabri, and documentation of risk factors such as anti-JCV antibody status and duration of therapy. The settlement process evaluates whether the manufacturer provided adequate warnings and whether monitoring protocols were followed.

What are the risk factors for developing PML from Tysabri?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating and continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.